WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Chronic Kidney Disease:
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
Use the lowest PROCRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions].
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Table 2, Warnings and Precautions].
Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance [see Warnings and Precautions].
To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration].
Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage].
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage].
Discontinue following the completion of a chemotherapy course [see Dosage and Administration].
Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration and Warnings and Precautions].
PROCRIT (epoetin alfa) is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin.
Anemia Due to Chronic Kidney Disease
PROCRIT is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.
Anemia Due to Zidovudine in HIV-infected Patients
PROCRIT is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.
Anemia Due to Chemotherapy in Patients With Cancer
PROCRIT is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery
PROCRIT is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. PROCRIT is not indicated for patients who are willing to donate autologous blood pre-operatively.
Limitations of Use
PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being.
PROCRIT is not indicated for use:
- In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
- In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
- In patients scheduled for surgery who are willing to donate autologous blood.
- In patients undergoing cardiac or vascular surgery.
- As a substitute for RBC transfusions in patients who require immediate correction of anemia [see Clinical Pharmacology].
Media Articles Related to Procrit (Epoetin Alfa)
FDA approves extended dosing of Aranesp
Source: The Doctors Lounge - Hematology
FDA has approved every-3-week dosing of Aranesp (darbepoetin alfa) for treatment of chemotherapy - induced anemia.
Published Studies Related to Procrit (Epoetin Alfa)
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. 
BACKGROUND: HX575, licensed under the brand names Binocrit(R), Epoetin Alfa Hexal(R), and Abseamed(R), was approved in 2007 as the first biosimilar recombinant human erythropoietin alfa (epoetin alfa) in the EU using Erypo(R)/Eprex(R) as reference product. OBJECTIVES: The aim of this study was to investigate the bioequivalence and potency of registered epoetin alfa products that have not been compared before in a randomized controlled clinical study... CONCLUSION: The results show, for the first time in a prospective randomized clinical study, equivalent bioavailability at steady state and similar potency of the US-marketed Epogen(R) and the European-marketed Binocrit(R). Differences in the formulation between the epoetin alfa products had no apparent clinical impact. The high degree of similarity between Epogen(R) and Erypo(R)/Eprex(R) provides justification for linking and comparing results from clinical studies that were conducted using either US- or European-marketed epoetin alfa products.
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. [2010.12]
BACKGROUND: Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of renal anaemia may be possible at extended dosing intervals; however, few studies were randomized, results varied, and comparisons between agents were absent. We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epoetin beta and darbepoetin alfa administered once monthly... CONCLUSIONS: Methoxy polyethylene glycol-epoetin beta maintained target haemoglobin more successfully than darbepoetin alfa at once-monthly dosing intervals despite dose increases with darbepoetin alfa.
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. [2010.10]
BACKGROUND: The conventional antiviral treatment of chronic hepatitis related to hepatitis C virus (HCV) often leads to anemia. In this case, it is necessary to reduce ribavirin dose or stop treatment, thus reducing the rate of sustained virological response. AIM: We investigated whether epoetin alpha administration improves treatment adherence and leads to higher percentage of response at the end of therapy and sustained virological response... CONCLUSIONS: In patients with 1b HCV-related chronic hepatitis who develop anemia during antiviral treatment, administration of epoetin alpha increases hemoglobin levels and the end-of-treatment rate and sustains virological response by improving treatment adherence.
Epoetin alfa reduces blood transfusion requirements in patients with intertrochanteric fracture. [2010.06]
PURPOSE: The purpose of this study is to identify the potential benefits or complications from the use of epoetin alfa in patients with intertrochanteric fracture... CONCLUSIONS: Patients with intertrochanteric fractures seem to benefit from the use of epoetin alfa because it is safe and reduces the need for blood transfusions. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. [2010.05.01]
PURPOSE: To determine whether epoetin alfa reduces anemia-related fatigue, improves other aspects of health-related patient-recorded outcomes (PROs), reduces the number of RBC transfusions, and has an impact on freedom from treatment failure (FFTF) and overall survival (OS) in patients with advanced-stage Hodgkin's lymphoma (HL)... CONCLUSION: Epoetin alfa administered at 40,000 U weekly parallel to BEACOPP chemotherapy was safe in patients with advanced-stage HL and reduced the number of RBC transfusions but had no impact on fatigue and other PRO domains.
Clinical Trials Related to Procrit (Epoetin Alfa)
The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery [Terminated]
The primary purpose of the study is to compare the effect of perioperative (the time period
describing the duration of a participants surgical procedure) administration of PROCRIT to
that of Standard of Care (SOC) on the proportion of participants receiving pRBC (packed red
blood cells) transfusions (from the day of surgery to the day of hospital discharge) in
participants undergoing elective major abdominal and/or pelvic surgery. Standard of Care is
defined as the treatment of participants according to the hospital or institution's policy,
but where participants will not receive PROCRIT (Epoetin alfa) or any other
erythropoiesis-stimulating agents (ESAs) (agents that stimulate the production of red blood
cells in the bone marrow).
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy [Terminated]
The purpose of this study is to compare hemoglobin response rates between two PROCRIT
(epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving
Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia [Withdrawn]
The purpose of this study is to find a better, more convenient way to improve anemia results
by increasing the amount of medication given at 3 week intervals. Researchers want to know
if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give
better results in treating anemia without the need for more office visits.
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa [Completed]
The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US
licensed reference product Epogen®/Procrit® when applied subcutaneously. This study is
intended to generate data supporting that the efficacy and safety under treatment with HX575
and Epogen®/Procrit® are comparable.
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease [Completed]
The purpose of this study is to demonstrate that once weekly and once every-2-weeks
treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease,
is not less effective than the approved treatment with epoetin alfa that is given 3 times
weekly with respect to changes in hemoglobin.
Reports of Suspected Procrit (Epoetin Alfa) Side Effects
Haemoglobin Decreased (69),
Therapeutic Response Decreased (50),
Aplasia Pure RED Cell (48),
Drug Ineffective (29),
Anti-Erythropoietin Antibody Positive (20),
Dyspnoea (19), more >>
Page last updated: 2011-12-09